ArticleScientific reports2026
Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Androgenetic alopecia (AGA) represents the most common form of hair loss, yet it lacks truly effective therapeutic options. Sesamum has been used for treating hair loss by ancient Chinese doctors. Nevertheless, the mechanism of sesamum is unclear. Sesamin is a key ingredient in sesamum, which shows multiple biological activities. We proposed that sesamin might improve influence molecular processes relevant to AGA by regulating the growth cycling of skin cells, and elucidated our proposal with in vitro researches. Network pharmacology was employed to predict sesamin-AGA targets and pathways. High-confidence targets were mapped into a protein-protein interaction network and functionally annotated by GO and KEGG enrichment. Molecular docking quantified binding affinities between sesamin and key proteins. Cytotoxicity was assessed by MTT in HaCaT keratinocytes. The regulatory capacity of sesamin was validated in DHT-stimulated HaCaT cells by Western blotting for AR, p38 MAPK, apoptosis (BAX/BCL2) and WNT10B signaling. Fifteen overlapping targets were identified, with AR, EGFR, ESR1 and CASP3 forming the core network. Enrichment analyses highlighted steroid hormone response, cell proliferation and MAPK/Wnt cascades. Docking showed high-affinity binding of sesamin to AR (- 9.1 kcal·mol⁻¹). Cell assays revealed that 10-80 µM sesamin reversed DHT-induced p38 phosphorylation, normalized AR expression, down-regulated pro-apoptotic BAX, restored anti-apoptotic BCL2, and elevated WNT10B. Our findings provided mechanistic evidences that sesamin modulates the AR-MAPK-Wnt signaling axis in DHT-challenged HaCaT cells, suggesting its potential multi-target activity against molecular events implicated in androgenetic alopecia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.